Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: Results from CALGB 80203 (Alliance)

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1078-1086

  Cushman, Stephanie M ^a,d   Jiang, Chen ^b   Hatch, Ace J ^a   Shterev, Ivo ^b   Sibley, Alexander B ^b   Niedzwiecki, Donna ^b   Venook, Alan P ^c   Owzar, Kouros ^b   Hurwitz, Herbert I ^a   Nixon, Andrew B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Alliance Statistical and Data Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; AMPHIREGULIN; BETACELLULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIGEN; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; ANTINEOPLASTIC AGENT; B RAF KINASE; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; AREG GENE; ARTICLE; BTC GENE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DUSP4 GENE; EGF GENE; EGFR GENE; EPGN GENE; ERBB2 GENE; ERBB3 GENE; ERBB4 GENE; EREG GENE; FEMALE; GENE; GENE EXPRESSION; HBEGF GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTANT; NT5E GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PHLDA1 GENE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TGFA GENE; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929455792     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2313     Document Type: Article

References (45)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
2. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney M, O'Neil BH, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32: 5s, 2014 (suppl; abstr LBA3).
3. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25: 282-303.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
6. Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009; 77: 57-68.
7. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-27.
8. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
9. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34.
10. Modest D, von Weikersthal LF, Stintzing S, Decker T, Kiani A, Vehling-Kaiser U, et al. O-0029folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment of kras-wildtype metastatic colorectal cancer: German aio study KRK-0306 (FIRE-3). Ann Oncol 2013; 24:iv22-iv3.
11. Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, et al. A genome-wide survey of RAS transformation targets. Nat Genet 2000; 24: 144-52.
12. Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, et al. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and isapromising therapeutic targetin non-small-cell lung cancer. Oncogene 2013; 32: 4034-42.
13. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
14. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation byrelieving a negative feedback on ERBB receptors. Cancer Res 2012; 72: 3228-37.
15. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
16. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30: 2547-57.
17. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications fortargeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
18. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068-74.
19. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011; 104: 488-95.
20. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) + cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24: 18s, 2006 (suppl; abstr 3509).
21. Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, et al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 2014; 110: 648-55.
22. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
23. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
24. Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, et al. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol 2014; 140: 737-48.
25. Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer 2014; 13: 105.
26. Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, et al. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO J 1997; 16: 5608-17.
27. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-41.
28. Gala K, Chandarlapaty S. Molecularpathways: HER3 targeted therapy. Clin Cancer Res 2014; 20: 1410-6.
29. Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 2011; 16: 53-60.
30. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Giustini L, Silva R, et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann Oncol 2012; 23: 1706-12.
31. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 7242-51.
32. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19: 355-67.
33. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993-1002.
34. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factorscontrol Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36: 362-73.
35. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012; 33: 231-7.
36. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res 2010; 70: 6407-11.
37. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998; 161: 95-109.
38. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16: 16-26.
39. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a preEmptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-7.
40. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol 2013; 171: 1-7.
41. Whiteside TL Regulatory Tcell subsetsinhuman cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014; 63: 67-72.
42. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-65.
43. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating Tcytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-71.
44. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285: 7176-86.
45. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527-35.